Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Depreciation & Amortization (CF) of $468000.0 for Q1 2026, little changed on a QoQ basis from $467000.0 in Q4 2025, and up 35.65% year-over-year from $345000.0 in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $468000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 35.65% year-over-year to $468000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 6.54% YoY) and the FY2025 annual result came in at $1.6 million, down 8.32% from the prior year.
- Depreciation & Amortization (CF) was $468000.0 for Q1 2026 at Kiniksa Pharmaceuticals International, roughly flat from $467000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $656000.0 in Q1 2022 and bottomed at $345000.0 in Q1 2025.
- A 5-year average of $497647.1 and a median of $468000.0 in 2026 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 110.26% — and 2024, when it sank 33.83%.
- Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) stood at $602000.0 in 2022, then fell by 10.3% to $540000.0 in 2023, then retreated by 25.93% to $400000.0 in 2024, then climbed by 16.75% to $467000.0 in 2025, then gained by 0.21% to $468000.0 in 2026.
- Business Quant data shows KNSA's Depreciation & Amortization (CF) at $468000.0 in Q1 2026, $467000.0 in Q4 2025, and $384000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 468,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,000.00 |
| Mar 31, 2026 | 468,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Jun 30, 2025 | 358,000.00 |
| Jun 30, 2025 | 358,000.00 |
| Mar 31, 2025 | 345,000.00 |
| Mar 31, 2025 | 345,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Sep 30, 2024 | 399,000.00 |
| Sep 30, 2024 | 399,000.00 |
| Jun 30, 2024 | 430,000.00 |
| Jun 30, 2024 | 430,000.00 |
| Mar 31, 2024 | 466,000.00 |
| Mar 31, 2024 | 466,000.00 |
| Dec 31, 2023 | 540,000.00 |
| Dec 31, 2023 | 540,000.00 |